Ulcerative Colitis significantly reduced by 480,000 IU loading dose of nano Vitamin D – RCT
Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial.
Letter to Editor on this study is at end of this page
J Clin Gastroenterol. 2019 Jul 26. doi: 10.1097/MCG.0000000000001233.
Ahamed Z R1, Dutta U1, Sharma V1, Prasad KK1, Popli P1, Kalsi D1, Vaishnavi C1, Arora S1,2, Kochhar R1.
1 Department of Gastroenterology.
2 Dept of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
1. Nano forms of Vitamin D
* Nanoemulsion Vitamin D may be a substantially better form
* Inhaled vitamin D help lungs - many studies
* Vitamin D nanoemulsion etc. for fortification, pills, injections, topical and cancer – July 2019
Types of UC
INTRODUCTION: Vitamin D possesses anti-inflammatory properties and could be beneficial in ulcerative colitis (UC).
METHODS:
We studied the effect of oral nano vitamin D3 supplementation on disease activity in active UC [ulcerative colitis disease activity index (UCDAI)≥3]. Patients with active UC and vitamin D <40 ng/mL were randomized to receive either oral nano vitamin D (60,000 IU/d×8 d) or placebo. They were evaluated for disease activity (UCDAI scores, C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin) at baseline and reassessed at 4 weeks. The response was defined as a 3-point reduction in UCDAI score at 4 weeks and reduction in inflammatory markers.
RESULTS:
The median vitamin D levels increased from 15.4 to 40.83 mg/dL in vitamin D group (P≤0.001) and marginally from 13.45 to 18.85 mg/dL (P=0.027) in controls.
The 3-point reduction in UCDAI was seen more often in vitamin D group as compared with the control (53% vs. 13%; P=0.001).
Increase in vitamin D levels correlated with reduction in UCDAI score (P≤0.001; ρ=-0.713), C-reactive protein (P≤0.001; ρ=-0.603), and calprotectin (P=0.004; ρ=-0.368).
Patients who achieved target vitamin D of >40 ng/mL (n=17) more often had a 3-point reduction in UCDAI (80% vs. 20%; P≤0.001) and reduction in grade of severity from 60% to 35% (P=0.038).
Vitamin D administration (odds ratio, 9.17; 95% confidence interval, 2.02-41.67) and baseline histologic activity (odds ratio, 1.92; 95% confidence intervals, 1.2-3.08) independently predicted response.
CONCLUSIONS:
Oral nano vitamin D supplementation in active UC is associated with a reduction in disease activity and severity grade and is seen more often in those who achieved a target vitamin D level of 40 ng/mL.
Oral Nano Vitamin D Supplementation and Disease Activity in Ulcerative Colitis
Journal of Clinical Gastroenterology: September 12, 2019 -doi: 10.1097/MCG.0000000000001263
Dai, Cong MD, PhD; Jiang, Min MD, PhD; Sun, Ming-Jun MD, PhD
Letter to the Editor: PDF Only
Image from the web
